About

Brian Di Donato serves as the Chief Executive Officer of ADAXION Therapeutics, where he leads the company in the development of pioneering deimmunized therapeutic proteins through antigen-specific B cell silencing. Prior to joining ADAXION Brian was the Chief Financial Officer and Head of Strategy at Immunocore, a commercial stage T-cell engaging company, where he oversaw financial operations, business development, investor relations and strategic planning for novel t-cell therapies for cancer and infectious diseases.

Brian’s track record includes successful leadership roles in both biotech and finance. As CFO of Achillion Pharmaceuticals, he helped guide the company to a $1.1 billion acquisition by Alexion Pharmaceuticals. Prior to Achillion Brian held multiple leadership roles in private equity and investment banking. Brian’s diverse experience spanning multiple sectors underscores a comprehensive understanding of the research, development, commercial and corporate finance challenges of the biotech industry.

Brian serves as Audit Committee Chair on the Board of Directors at iECURE, inc, a novel liver directed gene insertion biotech company. He holds a BS in biology from Penn State, a BS in mechanical engineering from Villanova University and an MBA from NYU Stern School of Business.